GGPS1 and plasma cell myeloma: Investigations focusing specifically on selective inhibitors of the human GGPPS for the treatment of hematopoietic malignancies have so far focused mainly on multiple myeloma (MM).14–18, Additionally, one report focused on acute lymphoblastic leukemia (ALL), using the digeranyl compound 1, a selective inhibitor of GGPPS.